Medindia

X

Nearly Half of Surveyed U.S. Payers Agree That Pharmacy-Level Substitution of Biosimilars is a Good Idea

Thursday, July 22, 2010 Drug News J E 4
Advertisement


WALTHAM, Mass., July 21 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that when U.S. payers were asked about substitution of biosimilars for branded biologics at the pharmacy level, nearly half (48 percent) agreed that it was a good idea. However, according to Decision Resources' Biosimilars Advisory Service: U.S. and EU Payer Perspectives, most surveyed U.S. payers believe that biosimilars are similar to reference biologics, but not identical, believing that biosimilars may have significant clinical differences with their reference products.

The report also finds that a majority (69 percent) of surveyed U.S. payers say they are moderately to very familiar with biosimilars, while 17 percent say they are slightly familiar with biosimilars.

"The high levels of reported familiarity may be because while media coverage of biosimilars is increasing, payers may feel less familiar with overall biosimilars regulation because of the recent myriad of legislative developments in the U.S. around healthcare reform," said Decision Resources Product Director Michael Malecki, Ph.D.

The U.S. and EU Payer Perspectives module offers primary research on payer attitudes toward biosimilar adoption, reimbursement and market drivers. It is offered as part of Decision Resources' Biosimilars Advisory Service that provides insight and analysis of the evolving biosimilars market.

Analyst Call

Members of the media are welcome to attend our upcoming analyst call entitled Payer Perspectives of Biosimilars: Priorities, Barriers to Entry and Opportunities. This analyst call will be held on Tuesday, July 27 at 10 a.m. U.S. Eastern Time. For more information, please contact Lisa Osgood at 781-296-2606 or by e-mail at losgood@hl-isy.com.

About the Biosimilars Advisory Service

Biosimilars Advisory Service from Decision Resources provides insight and analysis that's vital to successful business planning in the rapidly evolving biosimilars space. The service includes quarterly webinars detailing major developments, analyst calls addressing key market changes and opportunities and therapeutic area-specific primary research and forecasting modules.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact: Decision Resources Decision Resources, Inc. Lisa Osgood Christopher Comfort 781-296-2606 781-296-2597 losgood@hl-isy.com ccomfort@dresources.com

SOURCE Decision Resources
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
RF TechnologiesŪ Announces Version 7 Software for ...
S
Multiple Factors, Primarily Generic Erosion, Will ...